A Phase I, Open-label Study to Evaluate the Absorption, Metabolism, and Excretion and to Assess the Absolute Bioavailability Following a Single Oral Dose of [14C]-Tebapivat and Concomitant Single Intravenous Microdose of [13C2,15N3]-Tebapivat to Healthy Male Participants
Latest Information Update: 21 Mar 2025
At a glance
Most Recent Events
- 18 Mar 2025 Status changed from recruiting to completed.
- 27 Jan 2025 Status changed from not yet recruiting to recruiting.
- 26 Dec 2024 New trial record